Background: Medullary thyroid carcinoma (MTC) has varying clinical course with familial cases (fMTC) diagnosed earlier than sporadic MTC (spMTC). Methods: A total of 273 MTCs (familial: n = 110 [40.3%], males: 38.5%) were followed for 1-35 years (median 5.0 years). Fifty one of the familial cases were operated because of positive findings at genetic screening. Disease extent at diagnosis and follow-up was recorded. Results: Mean age at diagnosis was: fMTC = 33.85 AE 16.5 years (range 4-74) and spMTC = 52.6 AE 14.0 years (range 16-81, P < .001). This difference remained when genetic screening cases were excluded. fMTCs had more frequently multifocality, smaller size, and more favorable stage at diagnosis (stages I and II: 60.9% vs 47.9%, stage III: 30.0% vs 23.9%, stage IV: 9.1% vs 28.9%, P = .01). fMTC had lower preoperative and postoperative calcitonin, more frequently remission (59.1% vs 47.2%) and less frequently progressive disease (8.2% vs 35.0%, P < .001). After excluding genetic screening cases, no difference in stage at diagnosis was observed. Outcome was more favorable in fMTC compared to sporadic (P = .002); the 10-year probability of lack of progression of disease differed significantly between fMTCs and spMTCs (86.4% vs 65.0%, P < .001). Conclusion: After excluding genetic screening cases, although stage at diagnosis is similar, disease outcome remains worse in sporadic compared to fMTCs.
| INTRODUCTION
Medullary thyroid carcinoma (MTC) is a rare thyroid tumor accounting for 5%-8% of thyroid malignancies. It derives from the thyroid C-cells. In recent years routine screening of nodular disease with calcitonin measurements has been adopted in many centers, as it has been argued that such policy may lead to MTC diagnosis at an earlier stage and thus to better outcome; however this policy remains controversial. 1, 2 MTC is familial in 25% of cases (fMTC). fMTC occurs in the setting of three syndromes: the fMTC syndrome and the multiple endocrine neoplasia type 2A (MEN-2A) and 2B (MEN-2B) syndromes; they are associated with activating point mutations in the rearranged during transfection (RET) proto-oncogene. The molecular study identifies gene carriers and thus prophylactic thyroidectomy may be performed. [3] [4] [5] MTC has varying clinical course. Some studies have investigated the clinical characteristics and the disease outcome with respect to the familial nature of the disease. Although it has been suggested that sporadic MTC (spMTC) may have more aggressive course than familial disease, there are also studies that report a similar or even worse outcome in fMTCs compared to sporadic. [6] [7] [8] [9] [10] [11] [12] Thus, it is not well established whether familial disease per se has a more favorable clinical course. Our hypothesis is that increased awareness and earlier intervention may have influenced the outcome in these entities; thus we considered it worthwhile to reexamine this issue in a group of MTC patients followed in our Academic Endocrine Unit in Athens.
| PATIENTS AND METHODS
During the last 39 years, 273 MTC patients (38.5% males, n = 105) were seen in the Endocrine Unit of the Academic Department of Medical Therapeutics; all patients underwent total thyroidectomy, with or without lymph node dissection. They were followed up for 1-35 years (mean 7.5 AE 6.3, median 5.0 years). Of the 273 MTC patients, 222 had multinodular goiter (MNG); 161 of them (72.5%) were diagnosed with MTC after calcitonin screening. Fifty nine of them (26.5%) were carriers of a RET mutation and were assigned as fMTC index cases. A further 51 patients, relatives of index cases, were diagnosed with MTC after genetic screening. All cases included in the study underwent molecular analysis of the RET gene. Patients with positive RET mutation were considered as fMTC cases while those with no RET mutation were considered as spMTC.
The genetic analysis was performed in genomic DNA extracted from peripheral blood lymphocytes. The genetic screening for mutations in exons 8, 10, 11, 13, 14, and 16 of RET has been routinely performed since 2001 and for exon 15 since 2005; all apparent spMTC patients who had not undergone genetic screening were retrospectively analyzed for these mutations. We have previously reported that the exon 8 mutation (G533C) is quite common in Greece and in the Mediterranean region. 13 No patient was found to carry the exon 15 mutation in our cohort. A total of 163 patients (59.7%) were assigned to the spMTC group. In all patients belonging to the fMTC group except for one, a mutation in the RET gene has been identified (n = 110, 40.3%). This patient had MTC, bilateral pheochromocytomas, and no other features, while his son had a phenotype typical of the MEN2B syndrome confirmed through genetic analysis; both were considered as MEN2B, assuming that the father was a mosaic; however this has not been possible to prove. fMTC group included MEN-2A and MEN-2B casesaccording to the phenotype-as well as familial MTC cases.
14 Our unit is a referral center for MEN2 syndromes, thus our cohort is enriched in familial cases compared to the prevalence reported in the literature. 2 Of the 110 patients with familial disease, 51 were diagnosed after genetic screening (non-index fMTC) while 59 fMTC patients were index cases (index fMTC). Seven patients had MEN-2B (all index cases). We did not include in the analysis patients who were RET carriers and had undergone prophylactic thyroidectomy in which histology had shown C-cell hyperplasia. We recorded the age at diagnosis, the tumor size, the extent of disease at diagnosis and during follow-up, the number of surgeries performed as well as the preoperative and postoperative calcitonin levels. Staging at diagnosis was performed according to the American Joint Committee on Cancer TNM classification. 15 The majority of surgeries were performed in 3 different collaborating Surgery Units by high volume surgeons specializing in thyroid surgery. The type of surgical procedure (total thyroidectomy with or without lymph node dissection) was chosen according to the preoperative calcitonin levels, the neck ultrasound findings as well as the identification of suspect lymph nodes during the surgical procedure, as previously reported [16] [17] [18] and according to the relevant American Thyroid Association (ATA) guidelines. 14, 15 Patients with MNG and no preoperative calcitonin screening underwent initially total thyroidectomy and, when needed, lymph node dissection afterward. The patients with elevated preoperative calcitonin levels >20-50 pg/mL were advised for central lymph node dissection (level VI) and those with calcitonin >200 or >400 pg/mL (according to the relevant guidelines) were advised for lateral lymph node dissection (II-V). However in a minority of patients, the lymph node dissection was performed as a second surgery soon after thyroidectomy, while on some occasions central neck dissection was also performed soon after thyroidectomy irrespective of postoperative CT levels according to the patient's choice. For the purposes of our analysis, we divided patients according to the age at diagnosis in 3 groups (age groups: 4-25, 26-50, and ≥51 years). We further analyzed our data after grouping the fMTC patients according to the ATA risk classification (moderate, high, and highest risk). 14 Basal calcitonin and postoperative calcitonin levels were measured at 3 and 6 postoperative months and yearly thereafter. Patients with normal postoperative calcitonin (<1.5 pg/mL) and no lesions on imaging during the last visit were classified as being in remission; those with measurable postoperative calcitonin levels and no new imaging lesions were considered as having stable disease; those with either new or increasing size lesions had progressive disease according to response evaluation criteria in solid tumors criteria. 14, 19 Patients with increasing CT levels (≥150 pg/mL) and a doubling time <12 months were also considered as having progressive disease. 14, 20 Patients who were biochemically cured were reevaluated with ultrasound imaging; of those diagnosed before 2006, only 10 were lost to follow-up. International ELISA-hCT Kit (IRMA, Cis-Diagnostics, France) was used. Because the calcitonin method used before 2006 was less sensitive, we looked at the trend of postoperative calcitonin values over time for each patient; we did not observe changes that might potentially be due to the method used. In patients in remission who were diagnosed before 2006, calcitonin was also measured with the sensitive method during follow-up and the very low calcitonin levels measured earlier were confirmed. The study was conducted according to the Helsinki Declaration and was approved by the institutional review committee (Alexandra Hospital). All patients except those lost to follow-up were informed for the aim of the study and gave their consent.
| STATISTICAL ANALYSIS
Statistical analysis was done using the SPSS statistical package (version 18). All descriptive data are expressed as mean AE SD for normally distributed variables; otherwise, median value and intraquartile range (IQR) is shown. The chi-square statistic and the chi-square test for linear association (MantelHaenszel x 2 ) were used for contingency tables. For comparison of the means, the t test or the Mann-Whitney rank-test was used depending on normality of distribution. Analysis of variance or the Kruskal-Wallis test was used as appropriate. The Kaplan-Meier product limit method was used to estimate the probability of lack of disease progression within 10 years (120 months) after diagnosis. To evaluate which factors contribute to progression of disease, a univariate Cox proportional hazards model was used ("Enter" method); factors contributing to the outcome in univariate analysis at P < .05 were included in the multivariate model as potential risk factors (because of the risk of type II error attributable to low statistical power in such analysis). In the final multivariate analysis, statistical significance was set at 5% (P < .05).
| RESULTS

| Analysis in the whole cohort
Mean age at diagnosis for fMTC was 33.85 AE 16.5 (range 4-74 years) and for spMTC 52.6 AE 14.0 (range 16-81 years, P < .001). Age at diagnosis differed even when cases diagnosed after genetic screening were excluded from the analysis (38.9 AE 16.4 vs 52.6 AE 14.0, P < .001). The prevalence of familial disease was significantly higher in women than in men (46.4% vs 30.2%, P = .008).
Familial cases had more frequently multifocality, C-cell hyperplasia, microcarcinoma prevalence (P ≤ .02, Figure 1) , and smaller tumor size (fMTC vs spMTC 1.18 AE 0.77 vs 2.01 AE 1.66 cm, P < .001); soft tissue involvement, capsular invasion, and distant metastasis at diagnosis tended to be less frequent in fMTCs (Figure 1 ). No significant difference in the frequency of lymph node invasion was found (Figure 1) . At follow-up, fMTC had more frequently remission or stable disease and less frequently progressive disease (fMTC vs spMTC, remission: 59.1% vs 47.2%, stable: 32.7% vs 17.8%, progression: 8.2% vs 35.0%, P < .001). Familial cases had less frequently distant metastasis at follow-up compared to sporadic (8.2% vs 27.0%, P < .001). We further analyzed our data according to disease stage at diagnosis. No differences in the outcome were found in patients with stages I and II at diagnosis. However, significantly more unfavorable outcome was found in spMTCs compared to fMTCs when disease stage at diagnosis was III and IV (P = .018 and .04, respectively, Table 1 ). Further analysis in the different age subgroups showed that spMTCs had worse disease outcome compared to fMTCs in patients 26-50 years (P = .001) and in those ≥51 years (P = .008, Table 2) .
We further investigated possible differences in the disease features between fMTC cases identified through genetic screening (non-index cases), index fMTC cases, and spMTC cases. These results as well as the hazard ratios (HR) from the univariate analysis for disease outcome are listed in Table 3 . spMTCs had less favorable stage at diagnosis, less frequently remission, and less frequently stable disease at follow-up. Furthermore, spMTC showed progression of disease more frequently compared to fMTC (P < .001). Of those who underwent lymph node dissection at the first surgery (n = 159), disease progression was recorded in 4.2% of non-index (n = 1), in 16.2% (n = 6) of index cases, and in 45.9% (n = 45) of sporadic cases (P = .001). Of those who underwent ≥2 surgeries (n = 81), disease progression was FIGURE 1 Differences in clinical and histological characteristics between familial MTC (fMTC) and sporadic (spMTC) in the whole cohort recorded in none of non-index cases, in 37.5% (n = 6) of index fMTCs and in 73.2% (n = 41) of sporadic cases (P = .001). In multivariate Cox proportional hazard analysis, the type of the disease (non-index fMTC vs index fMTC vs spMTC), the disease stage at diagnosis, and the postoperative calcitonin levels were the only predictors of disease progression (Table 4) .
Furthermore, we analyzed our data after reclassifying fMTC patients according to the revised ATA guidelines risk classification 14 ; we found that "moderate risk" and "high risk" fMTCs had less progressive disease course compared to sporadic (P < .001, Table 5 ). However, when we compared sporadic cases with MEN2B cases which belong to the "highest risk" group, we found worse outcome in MEN2B (P = .012, Table 5 ).
In multivariate Cox proportional hazard analysis when age at diagnosis, familial form of disease, tumor size, disease stage at diagnosis, distant metastases at diagnosis, lymph node and soft tissue invasion, and preoperative and postoperative calcitonin levels were taken into account, the absence of familial form of disease and the disease stage at diagnosis were predictors of disease progression (HR: 9.8, 95% CI: 1.9-49.4, P = .006, and HR: 0.15, 95% CI: 0.03-0.7, P = .01, respectively). The 10-year probability of lack of progression of disease differed significantly when fMTC and spMTC patients were compared (91.8% vs 65.0%, KaplanMeier analysis, x 2 = 40.6, P < .001 for Log Rank). Moreover, when we included in the Kaplan-Meier analysis patients who were followed-up for more than 2 years, again similar differences were obtained (90.4% vs 63.9%, Kaplan -Meier analysis, x 2 = 40.6, P < .001).
| Results after excluding patients diagnosed through genetic screening
When analyses were performed excluding patients diagnosed after genetic screening, no difference in the stage at diagnosis was found between index fMTC and spMTC cases (P = .13 Figure 2 ). At stages I-III, no difference in the outcome was observed; however at stage IV, spMTC patients had more frequently disease progression (index cases fMTC vs spMTC: 55.6% [n = 5] vs 89.1% [n = 41], P = .03). More specifically, 72.7% of stage IVa, 81.3% of stage IVb, and 100% of stage IVc patients showed disease progression (P = .02). Similarly, after excluding MEN2B cases, index fMTCs at stage IV had less frequently disease progression compared to sporadic (50.0% vs 89.1% P = .04). When the age at diagnosis was considered, fMTC index cases had less frequently disease progression compared to spMTCs in the age group 25-50 years (9.1% vs 30.4%, P = .02) and the group ≥51 years (0.0% vs 38.5%, P = .002).
In the multivariate Cox proportional hazard analysis (in a similar model as mentioned above), the only predictors of disease progression were the absence of familial form of disease (HR: 5.4, 95% CI: 1.15-25.4, P = .03) and the stage at diagnosis (HR: 0.19, 95% CI: 0.042-0.9, P = .03). The 10-year probability of lack of progression of disease differed significantly between groups (fMTC vs spMTC: 86.4% vs 65.0%, KaplanMeier analysis, x 2 = 17.4, P < .001 for Log Rank, Figure 3 ).
| DISCUSSION
In our study, we examined possible differences in the clinical, biochemical, and histological characteristics at diagnosis and at follow-up between familial and sporadic forms of The first finding of our study concerns the mean age at diagnosis which was younger in familial cases even when only the index fMTC cases were included in the analysis. Similar results have previously been reported in the literature. 24, 25 Moreover, a higher incidence of familial disease was observed in females compared to males. A likely explanation for this finding is the higher level of awareness for genetic screening in females in the presence of family history of MTC. The results in the literature vary: a tendency for increased incidence of fMTC in women, 6 ,26,27 a similar female to male ratio, 8, 9 or even an increased frequency of familial disease in males 25, 28, 29 has all been reported.
We found that the disease stage at diagnosis was more favorable in fMTCs compared to spMTCs, when we included all patients in the analysis; however, further analysis which included only index cases of fMTC revealed no difference in disease stage at diagnosis. This finding stresses the importance of the genetic screening in detecting fMTC cases at an earlier stage as has been reported previously. 6, 23, 30 Moreover, in the whole cohort, preoperative as well as postoperative calcitonin levels were significantly lower in the familial compared to the sporadic form similar to previous reports. 25, 26 This is probably due to the detection of disease at an earlier stage in affected families through genetic screening. The most interesting finding of our study concerns the clinical outcome of the disease. fMTC had less frequently progressive disease, even after excluding patients diagnosed through genetic screening. To investigate further, we compared the disease outcome in the different subgroups taking into account the stage or the age at diagnosis. In these analyses, it was more clearly shown that fMTCs (analyzing either all-including MEN2B-or only the index cases) had more favorable clinical outcome when they were diagnosed at a more advanced stage (III or IV) or when they were diagnosed after the 25th year of their life. We should mention that we grouped the patients of stage IV subgroups (IVs, IVb, and IVc) together because the number of cases was rather small for analysis; it is possible that some of the differences arisen could be due to this fact. "Moderate" and "high risk" groups according to the ATA classification had less frequently progressive disease than spMTCs. MEN2B patients, as expected, had more severe disease than sporadic cases. A lower frequency of distant metastases at follow-up has previously been reported in fMTC supporting these findings. 25 Interestingly, in our study, the presence of the familial form of the disease and the more favorable stage at diagnosis were predictors of absence of disease progression. In an additional multivariate model, predictors of disease progression were similarly the type of the disease (non-index fMTC vs index fMTC vs spMTC), and the stage at diagnosis as well as the postoperative calcitonin levels. This finding highlights similar observations in older studies. [8] [9] [10] 12, 26 Similarly, Machens et al. have reported that RET carriers had less advanced disease than sporadic cases. 29 However, in some older studies, in which multivariate analysis was performed, fMTC history was not an independent prognostic factor for the disease outcome. 10, 12 On the other hand, 2 studies did not find differences in progression between sporadic and familial disease especially in patients with cervical metastatic disease at diagnosis. 7, 31 These discrepancies may be due to the fact that the majority of studies have included invariably all fMTC cases and have not excluded those diagnosed through genetic screening, which are expected to have less advanced disease. Furthermore, the 10-year probability of lack of progression of disease, which was decreased in fMTCs compared to spMTCs, confirms our findings, similar to previous reports. 9, 22, 24, 26, 28 The etiology of such differences in the clinical outcome between the 2 forms of MTC is not definitely known. The germline mutations of fMTC cases are also present in the tumors. On the other hand in sporadic tumors, somatic mutations in RET are present in approximately 20%-50% of the cases. 32 The M918 mutation is the most common one in sporadic tumors and is associated with more aggressive course and advanced disease stage at diagnosis. 33, 34 It should be noted that this mutation, when in the germline, is pathogenic for MEN-2B syndrome, which is the most aggressive form of fMTC. Thus, the presence of this mutation in some sporadic tumors could be one possible explanation for a more aggressive behavior than fMTC tumors, which harbor different RET mutations associated with less aggressive disease. It is also interesting that somatic RET mutations may be important for the progression of disease and not for the initiation of tumorigenesis. Such theory may be supported by the fact that somatic RET mutations are more frequent in larger spMTCs than in microcarcinomas. 35 Moreover, heterogeneity in the presence of RET mutation has been reported in subpopulations of tumor cells and in metastatic lesions. 36 Our study has several limitations: one is that molecular analysis of MTC tumors was not available. Moreover, our study is retrospective and concerns a rather small sample, with a short period of follow-up with a median of 5 years. Considering the slow progression of MTC and the long survival, longer follow-up is important. On the other hand it should be noted that, although sporadic cases were followed-up for a shorter period of time than familial ones, they showed more frequently disease progression. However, it should be stressed that the absence of family history was a predictor of disease progression independently of other confounding factors such as histopathological indices. This finding was still significant when only index cases of the fMTC group were analyzed.
| CONCLUSIONS
After excluding patients diagnosed through genetic screening, although stage at diagnosis is currently similar, disease outcome remains worse in spMTCs compared to fMTCs.
